RecruitingSphenopalatine BlockBOTOXChronic Migraine
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine
Eligible age
18–65 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.
Sponsor: Cairo University
You may qualify if…
- ✓ Age 18 and 65 years.
- ✓ Both sexes.
- ✓ Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta.
You may not qualify if…
- ✕ Patients with medication over use headache.
- ✕ Bleeding disorders.
- ✕ Abnormal neurological examination.
- ✕ History of allergy to local anesthetics or BOTOX.
Source: ClinicalTrials.gov · NCT06974617 · last updated 2025-05-16